# Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL

> **NCT06111625** · PHASE2 · RECRUITING · sponsor: **Sichuan University** · enrollment: 20 (estimated)

## Conditions studied

- Leukemia, Lymphoid

## Interventions

- **DRUG:** blinatumomab

## Key facts

- **NCT ID:** NCT06111625
- **Lead sponsor:** Sichuan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-10
- **Primary completion:** 2024-08-31
- **Final completion:** 2026-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06111625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06111625, "Short-term Blinatumomab as a Bridge Therapy for Allo-HSCT in Low Burden B-ALL". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06111625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*